Literature DB >> 20559525

The Significance of p53 and K-ras Immunocytochemical Staining in the Diagnosis of Malignant Biliary Obstruction by Brush Cytology during ERCP.

Young Sup Kim1, Ho Gak Kim, Jimin Han, Change Jae Hur, Byeong Suk Kim, Jin Tae Jung, Joong Goo Kwon, Eun Young Kim, Chang-Ho Cho, Yoon Kyung Sohn.   

Abstract

BACKGROUND/AIMS: Brush cytology during ERCP can provide a pathologic diagnosis in malignant biliary obstruction. K-ras and p53 mutations are commonly found in biliary and pancreatic cancers. We evaluated the diagnostic yield of brush cytology and the changes obtained by adding p53 and K-ras staining.
METHODS: One hundred and forty patients with biliary obstruction who underwent ERCP with brush cytology during a 7-year period were included. The sensitivity and specificity of brush cytology only and with the addition of p53 and K-ras staining were obtained.
RESULTS: Malignant biliary obstruction was confirmed in 119 patients. The sensitivity and specificity of brush cytology were 78.2% and 90.5%, respectively. The sensitivity of cytology was 77.3% at the ampulla-distal common bile duct (CBD), 92.6% at the mid common hepatic duct (CHD), and 94.7% at the proximal CBD-CHD (p<0.05); these values did not differ with the degree or the length of the obstruction. In the 97 patients who received additional p53 and K-ras staining, the sensitivity of cytology plus p53 was 88.2%, cytology plus K-ras was 84.0%, and cytology plus p53 and K-ras was 88.2%. The sensitivity of cytology plus p53 was higher than that of brush cytology only (95% confidence interval: 83.69-92.78 vs 72.65-83.65) but not that of cytology plus K-ras.
CONCLUSIONS: Brush cytology for malignant biliary obstruction has a high diagnostic accuracy. Adding p53 staining can further improve the diagnostic yield, whereas K-ras staining does not.

Entities:  

Keywords:  Brush cytology; ERCP; Immunocytochemical stain; Malignant biliary obstruction

Year:  2010        PMID: 20559525      PMCID: PMC2886932          DOI: 10.5009/gnl.2010.4.2.219

Source DB:  PubMed          Journal:  Gut Liver        ISSN: 1976-2283            Impact factor:   4.519


  32 in total

1.  Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study.

Authors:  Evan L Fogel; Mario deBellis; Lee McHenry; James L Watkins; John Chappo; Harvey Cramer; Suzette Schmidt; Laura Lazzell-Pannell; Stuart Sherman; Glen A Lehman
Journal:  Gastrointest Endosc       Date:  2006-01       Impact factor: 9.427

2.  Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.

Authors:  S T Dergham; M C Dugan; R Kucway; W Du; D S Kamarauskiene; V K Vaitkevicius; J D Crissman; F H Sarkar
Journal:  Int J Pancreatol       Date:  1997-04

3.  Biliary brush cytology: factors associated with positive yields on biliary brush cytology.

Authors:  Nasim Mahmoudi; Robert Enns; Jack Amar; Jaber AlAli; Eric Lam; Jennifer Telford
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

4.  Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases.

Authors:  J L Van Laethem; V Bourgeois; J Parma; M Delhaye; P Cochaux; T Velu; J Devière; M Cremer
Journal:  Gastrointest Endosc       Date:  1998-06       Impact factor: 9.427

5.  The establishment of a preoperative diagnosis of pancreatic carcinoma using cell specimens from pancreatic duct brushing with special attention to p53 mutations.

Authors:  T Iwao; K Hanada; A Tsuchida; M Hirata; N Eguchi; G Kajiyama
Journal:  Cancer       Date:  1998-04-15       Impact factor: 6.860

6.  Immunocytochemical detection of p53 protein as an adjunct in cytologic diagnosis from pancreatic duct brushings in mucin-producing tumors of the pancreas.

Authors:  T Iwao; A Tsuchida; K Hanada; N Eguchi; G Kajiyama; F Shimamoto
Journal:  Cancer       Date:  1997-06-25       Impact factor: 6.860

7.  Diagnostic value of brush cytology in the diagnosis of duodenal, biliary, and ampullary neoplasms.

Authors:  R H Bardales; M W Stanley; D D Simpson; S J Baker; C T Steele; R F Schaefer; C N Powers
Journal:  Am J Clin Pathol       Date:  1998-05       Impact factor: 2.493

8.  Diagnostic p53 immunostaining of endobiliary brush cytology: preoperative cytology compared with the surgical specimen.

Authors:  M Tascilar; P D Sturm; E Caspers; M Smit; M M Polak; K Huibregtse; L A Noorduyn; G J Offerhaus
Journal:  Cancer       Date:  1999-10-25       Impact factor: 6.860

9.  Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis.

Authors:  P D Sturm; E A Rauws; R H Hruban; E Caspers; T B Ramsoekh; K Huibregtse; L A Noorduyn; G J Offerhaus
Journal:  Clin Cancer Res       Date:  1999-03       Impact factor: 12.531

10.  Immunocytochemical detection of p53 protein from pancreatic duct brushings in patients with pancreatic carcinoma.

Authors:  S Ishimaru; M Itoh; K Hanada; A Tsuchida; T Iwao; G Kajiyama
Journal:  Cancer       Date:  1996-06-01       Impact factor: 6.860

View more
  3 in total

1.  Effects of endoscopic sphincterotomy on biliary epithelium: a case-control study.

Authors:  John Kalaitzis; Antonios Vezakis; George Fragulidis; Irene Anagnostopoulou; Spyros Rizos; Efstathios Papalambros; Andreas Polydorou
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

Review 2.  Brush Cytology, Forceps Biopsy, or Endoscopic Ultrasound-Guided Sampling for Diagnosis of Bile Duct Cancer: A Meta-Analysis.

Authors:  Seung Bae Yoon; Sung-Hoon Moon; Sung Woo Ko; Hyun Lim; Ho Suk Kang; Jong Hyeok Kim
Journal:  Dig Dis Sci       Date:  2021-07-14       Impact factor: 3.487

3.  Evaluation of Intraductal Ultrasonography, Endoscopic Brush Cytology and K-ras, P53 Gene Mutation in the Early Diagnosis of Malignant Bile Duct Stricture.

Authors:  Ping Huang; Hao Zhang; Xiao-Feng Zhang; Xiao Zhang; Wen Lyu; Zhen Fan
Journal:  Chin Med J (Engl)       Date:  2015-07-20       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.